Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015

Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.08, may not compare to the analyst estimate of ($0.16). Revenue for the quarter came in at $29.67 million versus the consensus estimate of $19.85 million.

Financial Guidance

With the recognition of royalty revenues of $30 million in July, the Company is raising its 2014 revenue guidance to approximately $105 million. The Company is also reducing its cash burn guidance for the year to $5 million to $10 million, and raising its guidance for year-end cash and marketable securities to $75 million to $85 million. The Company anticipates achieving profitability for the full year and being cash flow positive in 2015.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• First Bancorp. (FBNC) Misses Q1 EPS by 2c
• WM (WM) Tops Q1 EPS by 25c